Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of Cystadane in aspartylglucosaminuria
2017-000645-48Phase 2Completed
- Sponsor
- Minna Laine
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of betaine in aspartylglucosaminuria (AGU), sponsored by Minna Laine. Primary endpoint: Urinary excretion of glycoasparagines. Started May 2017; status: completed.
02
Drugs
betaine
03
Conditions
aspartylglucosaminuria (AGU)
Beyond the preview
Go deeper on 2017-000645-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000645-48.